MMP9
Matrix metalloproteinase-9
As of the edition of 20 October 2026, MMP9 (matrix metalloproteinase-9, UniProt P14780) has 4 drugs tested at it and 5 companies on the list, 3 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P14780
- How well studied
- Chemical tools exist; no approved drug acts on it
- Where it sits in the cell
- Secreted
- Solved structures
- 29
- Disease areas
- Cancer; Digestive system; Lungs and airways; Skin and connective tissue; Bones, joints and muscles; Inherited and neonatal; Immune system; Urinary and reproductive
- Registered trials of its drugs
- 29
Drugs at this target
| Status | Count |
|---|---|
| Active | 2 |
| Went quiet | 1 |
| Stopped | 1 |
| Total | 4 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Andecaliximab | Active | Phase 3 | none listed |
| AZD-1236 | Went quiet | Phase 2 | none listed |
| Rebimastat | Stopped | Phase 3 | none listed |
| Marimastat | Active | Phase 3 | none listed |
4 of 4 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 3 |
| Engaged | 2 |
| Total on the list | 5 |
| Company | Route |
|---|---|
| AstraZeneca | Route A |
| Bristol Myers Squibb | Route A |
| Gilead Sciences | Route A |
The other 2 companies at MMP9
In the product5 companies in all; 2 are not named here, and no score is.
See the 5 companies at MMP9, ranked, with the facts behind eachRequest access. Nothing is shown until you do.